A Phase-IV, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of Golimumab (MK-8259 [SCH 900259]) After Treatment Withdrawal, Compared With Continued Treatment (Either Full- or Reduced-Treatment Regimen), In Subjects With Non-Radiographic Axial Spondyloarthritis
Phase of Trial: Phase IV
Latest Information Update: 05 Dec 2017
At a glance
- Drugs Golimumab (Primary)
- Indications Spondylarthritis
- Focus Therapeutic Use
- Acronyms GO-BACK
- Sponsors Merck Sharp & Dohme
- 16 Nov 2017 Status changed from not yet recruiting to recruiting.
- 27 Oct 2017 Planned initiation date changed from 31 Oct 2017 to 9 Nov 2017.
- 31 Aug 2017 Planned End Date changed from 19 Sep 2022 to 3 Oct 2022.